Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
10 pending office actions • 9 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
MITSUBISHI TANABE PHARMA Corporation has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 distinct examiners across 9 distinct art units. Examiner assignments are fully distributed, while the art-unit data shows limited overlap in technical examination settings.
PORTER, RACHEL L is the busiest examiner, with 1 pending matter. The profile does not identify repeated examiner concentration. Counsel should therefore organize prosecution by application and art unit, while maintaining consistent positions on recurring pharmaceutical claim issues where the subject matter supports that approach.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (20%) |
| §103 only | 1 (10%) |
| §102 only | 2 (20%) |
| §112 only | 3 (30%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PORTER, RACHEL L | 1 | 21.5% | +24.5% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| GARTLAND, SCOTT D | 1 | 10.9% | +12.2% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| FERGUSON, JALISA HOLMES | 1 | 62.2% | +41.2% |
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| PETRASH, HILARY ANN | 1 | 65.6% | +50.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730540 | METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17258741 | PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED | PETRASH, HILARY ANN | 125d overdue |
| 18858801 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | PORTER, RACHEL L | — |
| 18715127 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | GARTLAND, SCOTT D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17258741 | PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED | PETRASH, HILARY ANN | 125d overdue |
| 17757955 | AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA | WANG, CHANG YU | 49d overdue |
| 17792673 | AGENT FOR PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY | MOSELEY II, NELSON B | 36d overdue |
| 18858801 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | PORTER, RACHEL L | — |
| 18872328 | SOLID FORMS OF RXFP1 MODULATORS | ISMAIL, REHANA | — |
| 17442798 | COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4 | SULLIVAN, STEPHANIE LAUREN | — |
| 18730540 | METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE | WILLIS, DOUGLAS M | — |
| 18715127 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | GARTLAND, SCOTT D | — |
| Art Unit | Apps |
|---|---|
| 3684 | 1 |
| 1625 | 1 |
| 1635 | 1 |
| 3685 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1642 | 1 |
| 1675 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858801 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | PORTER, RACHEL L | 3684 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 23, 2025 |
| 18872328 | SOLID FORMS OF RXFP1 MODULATORS | ISMAIL, REHANA | 1625 | §112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 17442798 | COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR MODULATING EXPRESSION OF DUX4 | SULLIVAN, STEPHANIE LAUREN | 1635 | §112 | Final Rejection | — | Pending | Aug 15, 2024 |
| 18730540 | METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE | WILLIS, DOUGLAS M | — | §112Other | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18715127 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PROGRAM | GARTLAND, SCOTT D | 3685 | §101§102§103§112 | Final Rejection | — | Pending | May 31, 2024 |
| 18172449 | COMPOUNDS AND THEIR USE | LEE, WILLIAM Y | 1623 | §102§112DP | Non-Final OA | — | Pending | Feb 22, 2023 |
| 17915794 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | FERGUSON, JALISA HOLMES | 1626 | §102 | Final Rejection | — | Pending | Sep 29, 2022 |
| 17792673 | AGENT FOR PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY | MOSELEY II, NELSON B | 1642 | §103 | Non-Final OA | 36d overdue | Pending | Jul 13, 2022 |
| 17757955 | AGENT FOR PREVENTING OR TREATING ACUTE-PHASE NEUROMYELITIS OPTICA | WANG, CHANG YU | 1675 | §102 | Non-Final OA | 49d overdue | Pending | Jun 24, 2022 |
| 17258741 | PREVENTION OR TREATMENT METHOD FOR PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS RECOGNIZED | PETRASH, HILARY ANN | 1644 | §102§103§112Other | Final Rejection | 125d overdue | Pending | Jan 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMITSUBISHI TANABE PHARMA Corporation has 10 pending office actions as of October 2026, spread across 9 art units and 10 examiners.
Rachel L Porter has the most, with 1 of MITSUBISHI TANABE PHARMA Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
